Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Autoimmune diseases and in particular type 1 diabetes rely heavily on treatments that target the symptoms rather than prevent the underlying disease. One of the barriers to better therapeutic strategies is the inability to detect and efficiently target rare autoreactive T-cell populations that are major drivers of these conditions. Here, we develop a unique artificial antigen-presenting cell (aAPC) system from biocompatible polymer particles that allows specific encapsulation of bioactive ingredients. Using our aAPC, we demonstrate that we are able to detect rare autoreactive CD4 populations in human patients, and using mouse models, we demonstrate that our particles are able to induce desensitization in the autoreactive population. This system provides a promising tool that can be used in the prevention of autoimmunity before disease onset.

Original publication

DOI

10.1021/acs.nanolett.2c00819

Type

Conference paper

Publication Date

06/2022

Volume

22

Pages

4376 - 4382

Addresses

Department of Materials, Department of Bioengineering and Institute for Biomedical Engineering, Imperial College London, Prince Consort Road, London SW7 2AZ, U.K.

Keywords

Antigen-Presenting Cells, T-Lymphocytes, CD4-Positive T-Lymphocytes, Animals, Humans, Mice, Diabetes Mellitus, Type 1, Autoimmunity